Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Novasep, a supplier of services and technologies for the life sciences industry, have signed an agreement for the manufacturing of adeno-associated virus (AAV) vectors.   The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Mutations in OTOF lea...